Expanded Access to ABT-414

AbbVie

Status

Conditions: Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis

Treatments: Drug: ABT-414

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT03123952

C19-919 (Other Identifier)

C16-478

Details and patient eligibility

About

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABT-414 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Participant must have epidermal growth factor receptor (EGFR) amplification or EGFRvIII mutation.
• Health Care Provider (HCP) must have prior clinical trial experience with ABT-414.
• The participant must not be eligible for an ABT-414 clinical trial.
• Pediatric participants may be evaluated on a case by case basis.